PL3253800T3 - Standardy antygenów prostaty i ich zastosowanie - Google Patents

Standardy antygenów prostaty i ich zastosowanie

Info

Publication number
PL3253800T3
PL3253800T3 PL16773820T PL16773820T PL3253800T3 PL 3253800 T3 PL3253800 T3 PL 3253800T3 PL 16773820 T PL16773820 T PL 16773820T PL 16773820 T PL16773820 T PL 16773820T PL 3253800 T3 PL3253800 T3 PL 3253800T3
Authority
PL
Poland
Prior art keywords
application
prostate antigen
antigen standards
standards
prostate
Prior art date
Application number
PL16773820T
Other languages
English (en)
Polish (pl)
Inventor
Vincent Linder
Christina Higgins
Original Assignee
Opko Diagnostics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics, Llc filed Critical Opko Diagnostics, Llc
Publication of PL3253800T3 publication Critical patent/PL3253800T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
PL16773820T 2015-03-27 2016-03-25 Standardy antygenów prostaty i ich zastosowanie PL3253800T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139365P 2015-03-27 2015-03-27
EP16773820.2A EP3253800B1 (en) 2015-03-27 2016-03-25 Prostate antigen standards and uses thereof
PCT/US2016/024149 WO2016160545A1 (en) 2015-03-27 2016-03-25 Prostate antigen standards and uses thereof

Publications (1)

Publication Number Publication Date
PL3253800T3 true PL3253800T3 (pl) 2021-08-23

Family

ID=56975150

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16773820T PL3253800T3 (pl) 2015-03-27 2016-03-25 Standardy antygenów prostaty i ich zastosowanie

Country Status (15)

Country Link
US (2) US11921115B2 (enExample)
EP (2) EP3318878A3 (enExample)
JP (1) JP6749337B2 (enExample)
CN (1) CN107406510B (enExample)
DE (1) DE202016008692U1 (enExample)
DK (1) DK3253800T3 (enExample)
ES (1) ES2867798T3 (enExample)
HU (1) HUE055020T2 (enExample)
IL (1) IL254412B (enExample)
MX (2) MX392040B (enExample)
PL (1) PL3253800T3 (enExample)
PT (1) PT3253800T (enExample)
TW (1) TWI698639B (enExample)
UA (1) UA124522C2 (enExample)
WO (1) WO2016160545A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
FI3312749T3 (fi) 2012-03-05 2024-05-31 Oy Arctic Partners Ab Menetelmiä ja laitteita eturauhassyövän riskin ja eturauhasen tilavuuden ennustamiseen
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
WO2016160545A1 (en) * 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
DE102015105979A1 (de) 2015-04-20 2016-10-20 Mankiewicz Gebr. & Co. Gmbh & Co. Kg Verbesserte Beschichtungssysteme, deren Verwendung zur Beschichtung von Bauteilen sowie damit beschichtete Bauteile für Windkraftanlagen
WO2017100457A1 (en) 2015-12-11 2017-06-15 Opko Diagnostics, Llc Fluidic systems involving incubation samples and/or reagents
CN108430639B (zh) 2015-12-29 2021-03-23 欧普科诊断有限责任公司 流体收集装置及相关方法
US12313834B2 (en) 2017-06-15 2025-05-27 Shenzhen Prs Limited Paraffin shield coating for microscope slide
US11662564B2 (en) 2017-06-15 2023-05-30 Shenzhen Prs Limited Paraffin shield coating for microscope slide
CN110753846B (zh) * 2017-06-15 2024-03-26 深圳市诺高实验器材有限公司 免疫组织化学抗原成像标尺外推方法

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
EP0725593B1 (en) 1993-10-28 2004-04-07 I-Stat Corporation Fluid sample collection and introduction device
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
CA2228485A1 (en) 1995-08-03 1997-02-20 Akzo Nobel Nv Diagnostic device
JP3645023B2 (ja) * 1996-01-09 2005-05-11 富士写真フイルム株式会社 試料分析方法、検量線の作成方法及びそれを用いる分析装置
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
CA2360073C (en) 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) * 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
CA2424941A1 (en) 2000-10-10 2002-04-18 Aviva Biosciences Corporation An integrated biochip system for sample preparation and analysis
ATE362107T1 (de) 2000-11-20 2007-06-15 Eastern Virginia Med School Verfahren und vorrichtungen zum quantitativen nachweis eines prostata-spezifischen membranantigens und anderer prostatamarker
AU2002362447A1 (en) 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
AU2002360499A1 (en) 2001-12-05 2003-06-17 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
JPWO2003100425A1 (ja) 2002-05-28 2005-11-04 株式会社常光 免疫学的クロマトグラフ法の試験紙片の読み取り定量装置
KR20110019357A (ko) 2002-08-06 2011-02-25 더 존스 홉킨스 유니버시티 난소암의 검출을 위한 생물 마커의 용도
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
US20050118061A1 (en) 2003-11-28 2005-06-02 Sysmex Corporation Analyzer, assay cartridge and analyzing method
AU2003292497A1 (en) 2003-12-10 2005-06-29 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A modular biochip assembly
CA2834041C (en) 2003-12-31 2017-05-16 President And Fellows Of Harvard College Assay device and method
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
ES2439225T3 (es) 2004-01-26 2014-01-22 President And Fellows Of Harvard College Sistema y método para el suministro de fluidos
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20050282199A1 (en) 2004-05-11 2005-12-22 Slawin Kevin M Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
KR20070043868A (ko) 2004-08-02 2007-04-25 칠드런'즈 메디컬 센터 코포레이션 암에 대한 혈소판 바이오마커
US7951529B2 (en) 2004-09-17 2011-05-31 The Johns Hopkins University Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122311A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Microfluidic chip
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
BRPI0709176A2 (pt) 2006-03-24 2011-06-28 Phenomenome Discoveries Inc. biomarcadores úteis para diagnosticar o cáncer de próstata e seus métodos
KR20090111307A (ko) 2006-07-03 2009-10-26 엑손히트 써라퓨틱스 에스에이 전립선 특이적 전사물 및 전립선암의 치료 및 진단에 사용되는 이의 용도
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
CA2673366C (en) 2006-12-22 2017-12-19 Phadia Ab Novel prostate kallikrein allergen
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
EP2156184B1 (en) 2007-05-08 2013-11-27 Picobella, LLC Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
US20090087860A1 (en) 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) * 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
CA2701945A1 (en) 2007-10-22 2009-04-30 Samuel Norbert Breit Methods of prognosis of overall survival using mic-1
US20090226912A1 (en) 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
US20110065605A1 (en) 2008-05-14 2011-03-17 Eth Zurich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
WO2010047767A2 (en) 2008-10-20 2010-04-29 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
WO2010080115A2 (en) 2008-12-18 2010-07-15 Claros Diagnostics, Inc. Improved reagent storage in microfluidic systems and related articles and methods
WO2010075446A1 (en) 2008-12-23 2010-07-01 Soar Biodynamics, Ltd. Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
SG10201401722XA (en) 2009-05-01 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy
DE112010002253T5 (de) 2009-06-04 2013-01-03 Charité - Universitätsmedizin Berlin Mittel und Verfahren zur Diagnostizierung von Prostatakarzinomen
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
EP2545079A2 (en) 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EA022356B1 (ru) 2010-04-16 2015-12-30 Опкоу Дайагностикс, Ллк Способ управления средами в микрофлюидных системах с обратной связью
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
US20140227720A1 (en) 2011-06-09 2014-08-14 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
CN106226527B (zh) * 2011-07-21 2018-05-04 和光纯药工业株式会社 血浆中氨基酸分析用内标液、内标物质及血浆中氨基酸的定量方法
JP6101274B2 (ja) 2011-10-28 2017-03-22 フレダックス・アクチエボラーグ 治療剤およびその使用
US20150044666A1 (en) 2012-01-13 2015-02-12 Iris International Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
FI3312749T3 (fi) 2012-03-05 2024-05-31 Oy Arctic Partners Ab Menetelmiä ja laitteita eturauhassyövän riskin ja eturauhasen tilavuuden ennustamiseen
JP2015524052A (ja) * 2012-05-16 2015-08-20 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 前立腺癌の存在または不存在の提示方法
EA201492284A1 (ru) 2012-06-27 2015-11-30 Берг Ллк Применение маркеров в диагностике и лечении рака предстательной железы
CN102818892B (zh) * 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
CA2891394C (en) 2012-11-20 2023-03-14 Phadia Ab Prognostic method for individuals with prostate cancer
JP2016503301A (ja) 2012-11-20 2016-02-04 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 侵攻性前立腺癌の存在または不存在を判定する方法
US10100125B2 (en) 2013-11-19 2018-10-16 Diaprost Ab Humanised anti kallikrein-2 antibody
FI3117216T3 (fi) 2014-03-11 2023-04-27 Phadia Ab Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
EP3268978A1 (en) 2015-03-12 2018-01-17 Thermo Finnigan LLC Methods for data-dependent mass spectrometry of mixed biomolecular analytes
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
EP3287786A3 (en) 2015-04-29 2018-03-21 Opko Diagnostics, LLC Compositions and methods for active surveillance of prostate cancer
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
WO2019221930A1 (en) 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Also Published As

Publication number Publication date
HUE055020T2 (hu) 2021-11-29
US20170370938A9 (en) 2017-12-28
TWI698639B (zh) 2020-07-11
PT3253800T (pt) 2021-04-28
CN107406510A (zh) 2017-11-28
UA124522C2 (uk) 2021-10-05
EP3318878A3 (en) 2018-07-11
US12510543B2 (en) 2025-12-30
DK3253800T3 (da) 2021-05-31
WO2016160545A1 (en) 2016-10-06
MX2022002138A (es) 2022-03-17
EP3253800A4 (en) 2018-11-07
MX2017012320A (es) 2018-01-18
JP6749337B2 (ja) 2020-09-02
MX392040B (es) 2025-03-21
TW201643429A (zh) 2016-12-16
CA2979559A1 (en) 2016-10-06
IL254412B (en) 2021-01-31
DE202016008692U1 (de) 2019-02-13
IL254412A0 (en) 2017-11-30
US11921115B2 (en) 2024-03-05
US20160282349A1 (en) 2016-09-29
EP3318878A2 (en) 2018-05-09
ES2867798T3 (es) 2021-10-20
EP3253800B1 (en) 2021-03-03
EP3253800A1 (en) 2017-12-13
US20240159758A1 (en) 2024-05-16
CN107406510B (zh) 2022-02-18
JP2018511055A (ja) 2018-04-19

Similar Documents

Publication Publication Date Title
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
PL3295951T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
PL4234581T3 (pl) Przeciwciała terapeutyczne i ich zastosowania
PL3303396T3 (pl) Przeciwciała przeciwko ox40 i ich zastosowanie
PL3443009T3 (pl) Przeciwciała i kompozycje anty-tim-3
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
IL280863A (en) Autotaxin inhibitors and uses thereof
PL3253800T3 (pl) Standardy antygenów prostaty i ich zastosowanie
PL3373755T3 (pl) Część do e-palenia i urządzenie do e-palenia oraz sposób ich wytwarzania
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PL3274370T3 (pl) Przeciwciała anty-ceacam6 i ich zastosowania
PL3215532T3 (pl) Przeciwciała anty-TIM3 i sposoby ich zastosowania
PL3922645T3 (pl) Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania
PL3313884T3 (pl) Przeciwciała anty-cd123 oraz ich koniugaty i pochodne
DK3201351T3 (da) Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3316909T5 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
PL3157552T3 (pl) Polipeptydy syntac i ich zastosowania
KR20180084891A (ko) 구조 조성물 및 방법
EP3363816A4 (en) ANTI-OX40 ANTIBODIES AND USES THEREOF
PL3280440T3 (pl) Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
PL3319612T3 (pl) Oksysterole i sposoby ich stosowania